CD19 Antibody (CVID3/155) - Azide and BSA Free

Name: CD19 Antibody (CVID3/155) - Azide and BSA Free
Brand: Novus Biologicals
SKU: NBP2-61908
Price: 559 USD
Availability: InStock

Novus Biologicals | Catalog # NBP2-61908

Submit a review

Product Documents

View Available Conjugates

100% Guarantee

Product Specifications
Scientific Data
Applications
Flow Cytometry
Preparation & Storage
Background
Product Documents
Specific Notices
Research Areas

Key Product Details

Species Reactivity

Human, Monkey

Applications

Flow Cytometry, Immunocytochemistry/ Immunofluorescence, CyTOF-ready

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG₁ kappa Clone # CVID3/155

Format

Azide and BSA Free

View all CD19 Primary Antibodies »

Product Specifications

Immunogen

Recombinant full-length human CD19 protein (Uniprot: P15391 )

Localization

Cell Surface

Marker

B-Lymphocyte Marker

Clonality

Monoclonal

Host

Mouse

Isotype

IgG₁ kappa

Theoretical MW

95 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Description

1.0 mg/ml of antibody purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS WITHOUT BSA & azide. Also available at 200 ug/ml WITH BSA & azide (NBP2-44674).

Antibody with azide - store at 2 to 8C. Antibody without azide - store at -20 to -80 C.

Scientific Data Images for CD19 Antibody (CVID3/155) - Azide and BSA Free

Immunocytochemistry/ Immunofluorescence: CD19 Antibody (CVID3/155) - Azide and BSA Free [NBP2-61908]

Immunocytochemistry/Immunofluorescence: CD19 Antibody (CVID3/155) - Azide and BSA Free [NBP2-61908] - Immunofluorescence staining of Raji cells. CD19 Antibody (CVID3/155) followed by goat anti-Mouse IgG-CF488 (Green). The nuclear counterstain is Red Dot (Red).

Flow Cytometry: CD19 Antibody (CVID3/155) - Azide and BSA Free [NBP2-61908]

Flow Cytometry: CD19 Antibody (CVID3/155) - Azide and BSA Free [NBP2-61908] - Flow cytometric analysis of lymphocyte-gated PBMCs. CD19 antibody (CVID3/155) labeled with CF568 (orange); unstained cells (gray).

Flow Cytometry: CD19 Antibody (CVID3/155) - Azide and BSA Free [NBP2-61908]

Flow Cytometry: CD19 Antibody (CVID3/155) - Azide and BSA Free [NBP2-61908] - Flow Cytometric Analysis of Raji cells. CD19 Antibody (CVID3/155) followed by goat anti-Mouse IgG-CF488 (Blue); Isotype Control (Red).

Applications for CD19 Antibody (CVID3/155) - Azide and BSA Free

Application

Recommended Usage

Flow Cytometry

0.5 - 1 ug/million cells in 0.1 ml

Immunocytochemistry/ Immunofluorescence

0.5 - 1.0 ug/ml

Application Notes

Optimal dilution for a specific application should be determined.

Flow Cytometry Panel Builder

Bio-Techne Knows Flow Cytometry

Save time and reduce costly mistakes by quickly finding compatible reagents using the Panel Builder Tool.

Advanced Features

Spectra Viewer - Custom analysis of spectra from multiple fluorochromes
Spillover Popups - Visualize the spectra of individual fluorochromes
Antigen Density Selector - Match fluorochrome brightness with antigen density

Build Your Panel Now

Formulation, Preparation, and Storage

Purification

Protein A or G purified

Formulation

10 mM PBS

Format

Azide and BSA Free

Preservative

No Preservative

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at -20 to -80C. Avoid freeze-thaw cycles.

Background: CD19

CD19 (Cluster of Differentiation 19), also known as B-lymphocyte surface antigen B4, is a type 1 transmembrane glycoprotein belonging to immunoglobulin (Ig) subfamily that serves as a biomarker for normal and neoplastic B cells (1,2). CD19 is a co-receptor for the B cell receptor (BCR) signaling complex and has a critical role in regulating B cell signaling and immune response (1,2). The CD19 protein contains an extracellular N-terminus containing two C2 Ig-like domains separated by a helical non-Ig domain, a single pass transmembrane domain, and a highly conserved cytoplasmic C-terminal domain (1,2). The human CD19 protein, encoded by the CD19 gene located on chromosome 16p11.2, is 556 amino acids (aa) in length with a calculated theoretical molecular weight (MW) of 61 kDa and an observed molecular weight of 95 kDa (1-3). CD19 associates with other molecules - CD21, CD81, and CD225 - to form the BCR co-complex, also called the CD19 complex, through CD21 binding to the complement C3d complex (1-3). Complement C3d bridges the BCR with the CD19 complex into lipid rafts of the plasma membrane (1-3). CD19 is capable of modulating B cell development through both BCR-dependent and -independent signaling (1-3). Upon BCR activation, the tyrosine residues of CD19's cytoplasmic tail recruits multiple kinases including Lyn, Vav, and PI3K, amplifying BCR-mediated immune signaling and B cell activation (1-3).

Considering the role of CD19 in BCR signaling and its expression in development from pre-B cells through plasma cells, it is understandable that CD19 dysfunction and abnormal expression is associated with numerous B cell malignancies and autoimmune disorders (1-5). CD19 expression is typically observed at relatively normal levels in B cell acute lymphoblastic leukemia (B-ALL) and chronic lymphoblastic leukemia (CLL) but is often reduced other types of lymphoma including diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) (1,2). On the other hand, CD19 expression is typically increased in autoimmune disorders such as systemic sclerosis (SSc) and multiple sclerosis (MS) as modeled by experimental autoimmune encephalomyelitis (EAE) (2). CD19 has become a therapeutic molecular target for the treatment of B cell lymphomas and autoimmune disorders using monoclonal antibodies (mAbs), bi-specific T cell engaging (BiTE) antibodies, and CD19-specific chimeric antigen receptor (CAR) T cells (1,2,4-6). Although anti-CD19 CAR T cell therapy has become the standard for the treatment of B cell malignancies, patients may experience relapse due to resistance mechanisms (6). Strategies to improve efficacy and limit relapse include combination of CAR T cell therapy with immune checkpoint inhibitors like anti-PD-1 (4,6).

References

1. Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1(1):36. https://doi.org/10.1186/2162-3619-1-36

2. Li X, Ding Y, Zi M, et al. CD19, from bench to bedside. Immunol Lett. 2017;183:86-95. https://doi.org/10.1016/j.imlet.2017.01.010

3. Wentink MWJ, van Zelm MC, van Dongen JJM, Warnatz K, van der Burg M. Deficiencies in the CD19 complex. Clin Immunol. 2018;195:82-87. https://doi.org/10.1016/j.clim.2018.07.017

4. Frigault MJ, Maus MV. State of the art in CAR T cell therapy for CD19+ B cell malignancies. J Clin Invest. 2020;130(4):1586-1594. https://doi.org/10.1172/JCI129208

5. Penack O, Koenecke C. Complications after CD19+ CAR T-Cell Therapy. Cancers (Basel). 2020;12(11):3445. https://doi.org/10.3390/cancers12113445

6. Bouziana S, Bouzianas D. Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy. Crit Rev Oncol Hematol. 2021;157:103096. https://doi.org/10.1016/j.critrevonc.2020.103096

Alternate Names

CD19, CVID3, Leu-12

Gene Symbol

CD19

Additional CD19 Products

Product Documents for CD19 Antibody (CVID3/155) - Azide and BSA Free

Download Product Datasheets

Download SDS

Product Specific Notices for CD19 Antibody (CVID3/155) - Azide and BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.